{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:46:30Z","timestamp":1791744390532,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hamad Medical Corporation","id":[{"id":"https:\/\/ror.org\/02zwb6n98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The Janus kinase 2 (JAK2) V617F mutation is recognized as a defining molecular lesion in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). This mutation was recognized in the context of clonal hematopoiesis of indeterminate potential, which has recently been linked with cardiovascular disease. Recent evidence has demonstrated a significant correlation between JAK2 mutations and thoracic aortic aneurysm (TAA) a condition frequently lacking identifiable risk factors\n                    <jats:bold>.<\/jats:bold>\n                    A scoping review, involving MEDLINE, Embase, Web of Science, Google Scholar, and prominent hematology and cardiology conference abstracts (from inception to August 2025) was performed. All studies that indicate a correlation between JAK2 mutations and aortic aneurysms were included. Seven studies with a total of 446,839 participants were found. Among these, 745 (0.17%) tested positive for JAK2. Data consistently indicated an elevated risk of thoracic aortic aneurysm (TAA), but not abdominal aortic aneurysm, in individuals with JAK2 mutations. Proposed mechanisms include inflammatory cytokine signaling, macrophage activation, and degradation of the extracellular matrix. Emerging clinical data indicate a consistent association between JAK2 V617F\u2013mutated clonal hematopoiesis or myeloproliferative neoplasms and thoracic aortic aneurysm, with less consistent findings for abdominal aneurysm. Although experimental studies suggest that JAK2-driven inflammatory signaling and extracellular matrix remodeling may contribute to vascular wall injury, these mechanisms remain largely inferential and do not establish causality. Well-designed prospective investigations incorporating standardized imaging, uniform aneurysm definitions, and stratification by clonal burden and disease context will be necessary to better define risk and determine whether JAK2-associated clonal hematopoiesis has implications for vascular surveillance or prevention strategies.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Summary of the study design, key results, and conclusions. Created with assistance from OpenAI ChatGPT (DALL\u00b7E image generation tool); all scientific content was reviewed and verified by the authors.<\/jats:p>","DOI":"10.1007\/s11239-026-03280-w","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:22:07Z","timestamp":1779189727000},"page":"1835-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between JAK2 mutations and thoracic aortic aneurysms in myeloproliferative neoplasms"],"prefix":"10.1007","volume":"59","author":[{"given":"Mohamad Wajeh","family":"Dulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Altermanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Kaddoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"Imam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"21","key":"3280_CR1","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker W, Constantinescu SN (2013) JAK\/STAT signaling in hematological malignancies. Oncogene 32(21):2601\u20132613. https:\/\/doi.org\/10.1038\/onc.2012.347","journal-title":"Oncogene"},{"key":"3280_CR2","doi-asserted-by":"publisher","unstructured":"How J, Garcia JS, Mullally A (2023) Biology and therapeutic targeting of molecular mechanisms in MPNs.\u00a0Blood,\u00a0141(16), 1922\u20131933. https:\/\/doi.org\/10.1182\/blood.2022017416 James C, et al. A unique clonal JAK2 mutation in idiopathic erythrocytosis. Nature. 2005.","DOI":"10.1182\/blood.2022017416"},{"issue":"19","key":"3280_CR3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180065","volume":"134","author":"WG Dunn","year":"2024","unstructured":"Dunn WG, McLoughlin MA, Vassiliou GS (2024) Clonal hematopoiesis and hematological malignancy. J Clin Invest 134(19):e180065. https:\/\/doi.org\/10.1172\/JCI180065","journal-title":"J Clin Invest"},{"issue":"26","key":"3280_CR4","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood.2023022222","volume":"142","author":"LD Weeks","year":"2023","unstructured":"Weeks LD, Ebert BL (2023) Causes and consequences of clonal hematopoiesis. Blood 142(26):2235\u20132246. https:\/\/doi.org\/10.1182\/blood.2023022222","journal-title":"Blood"},{"issue":"11","key":"3280_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41569-024-01081-3","volume":"21","author":"J Harman","year":"2024","unstructured":"Harman J (2024) Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD. Nat Rev Cardiol 21(11):741. https:\/\/doi.org\/10.1038\/s41569-024-01081-3","journal-title":"Nat Rev Cardiol"},{"issue":"6327","key":"3280_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andr\u00e9s V, Hirschi KK, Martin KA, Walsh K (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Sci (New York, NY) 355(6327):842\u2013847. https:\/\/doi.org\/10.1126\/science.aag1381","journal-title":"Sci (New York, NY)"},{"issue":"5","key":"3280_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101682","volume":"4","author":"LM Buja","year":"2025","unstructured":"Buja LM, Zhao B, Vela D, Segura A, Narula N (2025) Pathobiology of aortic aneurysms and dissections: synthesis of recent investigations and evolving insights. JACC Adv 4(5):101682","journal-title":"JACC Adv"},{"issue":"21","key":"3280_CR8","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/j.jacc.2023.03.413","volume":"81","author":"T Nakao","year":"2023","unstructured":"Nakao T, Yu Z, Vlasschaert C, Uddin MM, Lindsay ME, Ellinor PT, Ebert BL, Bick AG, Pirruccello JP, Natarajan P (2023) Increased risk of thoracic aortic aneurysms with JAK2 V617F. J Am Coll Cardiol 81(21):2128\u20132130. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.413","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3280_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.125.074002","volume":"152","author":"LM Obel","year":"2025","unstructured":"Obel LM, Skovbo JS, Diederichsen ACP, Thomassen M, Kj\u00e6r L, Larsen MK, Knudsen TA, Skov V, Kruse TA, Burton M, Dembic M, Wienecke T, Sabater-Lleal M, Gerke O, Bruun NE, Ellervik C, Brabrand M, Steffensen FH, Frost L, Lambrechtsen J, Busk M, Urbonaviciene G, Egstrup K, Karon M, Feddersen S, Rasmussen LM, Hasselbalch HC, Lindholt JS (2025) Aortic aneurysm risk and the somatic JAK2V617F mutation: insights from a multicenter, population-based cardiovascular screening study. Circulation 152(5):300\u2013312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.074002","journal-title":"Circulation"},{"key":"3280_CR10","unstructured":"Al-Rifai R, et al (2022) JAK2V617F drives vascular remodeling and aortic dilation in myeloproliferative neoplasms. Nat Commun"},{"issue":"9","key":"3280_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1161\/ATVBAHA.124.321008","volume":"44","author":"H Zhang","year":"2024","unstructured":"Zhang H, Kafeiti N, Masarik K, Lee S, Yang X, Zheng H, Zhan H (2024) Decoding endothelial MPL and JAK2V617F mutation: insight into cardiovascular dysfunction in myeloproliferative neoplasms. Arterioscler Thromb Vasc Biol 44(9):1960\u20131974","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3280_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00281-022-00913-z","volume":"44","author":"K Amancherla","year":"2022","unstructured":"Amancherla K, Wells JA 4th, Bick AG (2022) Clonal hematopoiesis and vascular disease. Semin Immunopathol 44(3):303\u2013308. https:\/\/doi.org\/10.1007\/s00281-022-00913-z. (Epub 2022 Feb 4. PMID: 35122117; PMCID: PMC9064918.)","journal-title":"Semin Immunopathol"},{"issue":"7","key":"3280_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3324\/haematol.2020.264085","volume":"106","author":"T Yokokawa","year":"2021","unstructured":"Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Morishita S, Komatsu N, Ikeda K, Takeishi Y (2021) Crucial role of hematopoietic\u00a0JAK2\u00a0V617F in the development of aortic aneurysms. Haematologica 106(7):1910\u20131922. https:\/\/doi.org\/10.3324\/haematol.2020.264085","journal-title":"Haematologica"},{"key":"3280_CR14","doi-asserted-by":"publisher","unstructured":"Waldron C, Zafar MA, Ma D, Zhang H, Dykas D, Ziganshin BA, Popa A, Jha A, Kwan JM, Elefteriades JA (2024) Somatic Variants Acquired Later in Life Associated with Thoracic Aortic Aneurysms:\u00a0JAK2\u00a0V617F. Genes (Basel). 15(7):883. https:\/\/doi.org\/10.3390\/genes15070883. PMID: 39062663; PMCID: PMC11276600. Pena A, et al. Ruxolitinib prevents aneurysm formation in JAK2-mutant mice by suppressing IL-1 and MMPs. JCI Insight. 2021.","DOI":"10.3390\/genes15070883"},{"key":"3280_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100550","author":"D Ma","year":"2023","unstructured":"Ma D, Popa A, Dykas D, Ziganshin B, Zafar M, Elefteriades J, Zhang H, Bale A (2023) P503: historical prospective study of the link between JAK2-V617F and thoracic aortic aneurysm. Genet Med Open. https:\/\/doi.org\/10.1016\/j.gimo.2023.100550","journal-title":"Genet Med Open"},{"issue":"S3","key":"3280_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971012.83349.75","volume":"7","author":"J Grevet","year":"2023","unstructured":"Grevet J, Leiva O, Hobbs G, How J (2023) P1029: JAK2\u2011CHIP is associated with similar risk of cardiovascular disease as JAK2\u2011MPN. HemaSphere 7(S3):e8334975. https:\/\/doi.org\/10.1097\/01.HS9.0000971012.83349.75","journal-title":"HemaSphere"},{"issue":"1","key":"3280_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1159\/000541036","volume":"17","author":"AKA Yasin","year":"2024","unstructured":"Yasin AKA, Mohamed SF, Abdalla E, Rao G, Alkhulaifi AM, Yassin MA, Mudawi D, Al-Mashdali AF, Kohla S, Ibrahim FA, Soliman D, Carr CS (2024) JAK 2-Positive diseases and spontaneous coronary artery dissection: case series. Case Rep Oncol 17(1):1008\u20131013. https:\/\/doi.org\/10.1159\/000541036","journal-title":"Case Rep Oncol"},{"issue":"6","key":"3280_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/leu.2015.277","volume":"29","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A, Lasho TL et al (2015) JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis: clinical, hematologic, and molecular comparisons with JAK2 V617F. Leukemia 29(6):1312\u20131317. https:\/\/doi.org\/10.1038\/leu.2015.277","journal-title":"Leukemia"},{"issue":"10","key":"3280_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544\u20131551. https:\/\/doi.org\/10.1182\/blood-2013-11-539098","journal-title":"Blood"},{"issue":"1","key":"3280_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-024-01169-6","volume":"14","author":"MF McMullin","year":"2024","unstructured":"McMullin MF, Mead AJ, Ali S et al (2024) Myeloproliferative neoplasms and thrombosis: insights into the causal relationship. Blood Cancer J 14(1):13. https:\/\/doi.org\/10.1038\/s41408-024-01169-6","journal-title":"Blood Cancer J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03280-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03280-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:36:49Z","timestamp":1791743809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03280-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3280"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03280-w","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}